$CORT (CORCEPT THERAPEUTICS) — 8-K: Corcept President of Endocrinology Sean Maduck to retire; Justin Gunn named successor effective October 1

Justin Gunn will succeed Sean Maduck as President of Corcept's Endocrinology division, assuming responsibilities October 1 and reporting to CEO Joseph Belanoff. Maduck, who led the endocrinology business for 14 years, will remain as a senior commercial advisor to support the transition. Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division, where he built a new field sales and training organization supporting the launch of Lifyorli for platinum-resistant ovarian cancer. He previously spent nearly 18 years at Gilead Sciences.

Justin Gunn will succeed Sean Maduck as President of Corcept's Endocrinology division, assuming responsibilities October 1 and reporting to CEO Joseph Belanoff. Maduck, who led the endocrinology busin